Abstract
BackgroundHaemorrhagic cerebrovascular events have been reported during Alemtuzumab treatment for relapsing-remitting multiple sclerosis (RRMS) leading to changes in the marketing authorisation in Europe. Hypertension is the proposed mechanism.AimsTo characterise systolic...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have